A single 5-minute, non-invasive scan could enable more informed triage in overcrowded emergency departments.
AQMed is pioneering the use of advanced sensors and artificial intelligence — including Large Quantitative Models (LQMs) — to transform how heart disease is detected, diagnosed, and monitored.
Cardiovascular disease remains the leading cause of death globally — and early detection is still failing millions.
Source: World Health Organization
Source: CDC
Source: American Heart Association
CardiAQ, an investigational device, uses high-performance sensors designed to map the heart's magnetic fields, aiming to reveal underlying conditions that standard diagnostic tools like an EKG may not capture. Paired with AI-powered Large Quantitative Models (LQMs) and advanced electromagnetic interference rejection, CardiAQ is being developed to enable rapid, highly precise detection of ischemia and high-risk coronary artery disease (HRCAD).
Measures the heart's natural magnetic fields to potentially provide highly detailed data compared to traditional ECG.
No cryogenic cooling. Engineered to work in standard clinical environments, without infrastructure overhaul.
Aims to translate complex magnetic field maps into clean, automated reports that clinicians could act on immediately.
Designed to be Technician- or nurse-operated. Non-invasive. Radiation-free. Results in under 5 minutes.
AQMed is committed to clinical excellence through partnerships with top-tier academic medical centers, including Mount Sinai and Mayo Clinic. Our ongoing clinical studies are designed to rigorously evaluate CardiAQ's diagnostic accuracy for acute coronary syndrome (ACS) and ischemia against gold-standard methods. First focusing on high-risk coronary artery disease, we are building the definitive evidence needed to transform cardiac care at the point of care.
Results from Our Clinical Partners
Case Study
Study participant 035
Patient presented to the emergency department with chest pain requiring evaluation for a potential acute cardiac event.
ECG and troponin testing were negative, with no indication of acute coronary syndrome (ACS).
An investigational CardiAQ MCG scan was completed in approximately 5 minutes. Results were not used for clinical care.
Based on conventional testing, the patient was discharged with a diagnosis of GERD.
The patient returned with severe chest pain. A repeat ECG confirmed STEMI.
Outcome: 100% Mid-LAD occlusion. Patient received 4 stents.
MCG Advantage
A 5-minute, non-invasive MCG scan can reveal the heart’s unique magnetic signature. Preliminary analysis suggests this patient could have been identified as abnormal nearly 6 hours earlier.
Partner on clinical research. We work with academic medical centers, health systems, and research institutions to advance MCG science. If you're a cardiologist, clinical researcher, or hospital innovation lead, let's talk.
We're hiring physicists, ML engineers, biomedical scientists, and clinical operations specialists. Come apply quantum technology and AI to one of medicine's most important unsolved problems.
Inside SandboxAQ: Building Frontier Medical Technology
My AQ Journey | Christian Nguyen
Beyond the EKG: Using Quantum Sensors to Detect Heart Attacks
From the Lab to Hospital Bedside: How Magnetic Fields Can Detect Heart Attacks Faster
Rebuilding Heart Signals from Noise: The Science Behind SandboxAQ’s MCG Device
AQMed: The Future of Cardiac Diagnostics
How CardiAQ Works — Technical Demo
Abstract 4140246: AI and Quantum Sensors: Realization of a Safe and Effective Unshielded Bedside Magnetocardiogram to Detect Ischemia in the Emergency Room
Abstract 15392: Performance of a Novel Unshielded Magnetocardiography Device in a First-in-Human Study
Bedside Magnetocardiography with a Scalar Sensor Array
26-A-11705-ACC EMERGENCY DEPARTMENT TRIAGE OF PATIENTS WITH SUSPECTED ACUTE CORONARY SYNDROME USING UNSHIELDED MAGNETOCARDIOGRAPHY
26-A-11614-ACC MACHINE LEARNING-BASED DETECTION OF CORONARY ARTERY DISEASE USING UNSHIELDED MAGNETOCARDIOGRAPHY
Magnetocardiography (MCG) is a non-invasive cardiac diagnostic technique that measures the magnetic fields generated by the heart's electrical activity. Unlike a standard EKG, which measures voltage on the skin surface, MCG captures a three-dimensional map of cardiac magnetic fields.
CardiAQ uses high-performance sensors to detect magnetic signals from the heart that are invisible to a standard EKG. Combined with AI-powered Large Quantitative Models (LQMs), CardiAQ could identify cardiac abnormalities earlier, without requiring skin contact, conductive gel, or electrode placement.
No. CardiAQ is designed to operate in standard clinical environments. Its sensor technology and AI-powered noise cancellation algorithms eliminate the need for expensive shielded rooms, a major barrier for previous MCG systems.
CardiAQ is currently an investigational device. It has not yet been cleared or approved by the FDA. AQMed is actively conducting clinical studies to support a future regulatory submission.
We collaborate with academic medical centers, health systems, cardiology practices, and research institutions. If you're a cardiologist, clinical researcher, or hospital innovation lead, we welcome partnership inquiries.
AQMed has active research collaborations with UCSF, Mount Sinai West, and Mayo Clinic. Additional clinical sites are being evaluated for future studies.
AQMed is the medical diagnostics business unit of SandboxAQ, a company focused on AI and quantum technology applications. AQMed leverages SandboxAQ's expertise in Large Quantitative Models (LQMs) and advanced sensing to develop next-generation cardiac diagnostic tools.
Investigational Device
CardiAQ is an investigational device. Limited by Federal law to investigational use. It has not been cleared or approved by the U.S. Food and Drug Administration (FDA). It is not available for commercial sale or clinical use. The information on this page is intended for research and educational purposes only and does not constitute medical advice.
